(66 days)
Not Found
No
The description explicitly states the use of "well-established algorithms" for generating parametric maps and does not mention AI or ML.
No
The device is described as a software application that performs post-processing and display of existing MRI data to generate parametric perfusion maps. It does not exert any direct action on the patient and is intended to provide information to a trained physician for interpretation, rather than directly treating or diagnosing.
Yes
Explanation: The device generates "parametric perfusion maps" using existing MRI data, which "when interpreted by a trained physician may yield information useful in clinical applications." This indicates the device processes medical images to provide information for diagnosis or treatment planning.
Yes
The device is explicitly described as a "software application" and "multi-platform software running on any Windows, Mac and Linux operating systems," with no mention of accompanying hardware components. Its function is solely the post-processing and display of data from existing MRI systems.
Based on the provided information, PERFSCAPE is not an In Vitro Diagnostic (IVD) device.
Here's why:
- IVD Definition: In Vitro Diagnostics are devices intended for use in the examination of specimens derived from the human body in order to provide information for diagnostic purposes. This typically involves analyzing biological samples like blood, urine, tissue, etc.
- PERFSCAPE's Function: PERFSCAPE analyzes imaging data (Magnetic Resonance datasets) acquired from within the human body. It processes and displays these images to generate parametric maps. It does not analyze biological specimens.
- Intended Use: The intended use clearly states it "allows the post-processing and display of dynamically acquired Magnetic Resonance datasets to evaluate image intensity variations over time." This is image analysis, not in vitro analysis of biological samples.
Therefore, PERFSCAPE falls under the category of medical imaging software or image processing software, not an IVD.
N/A
Intended Use / Indications for Use
PERFSCAPE allows the post-processing and display of dynamically acquired Magnetic Resonance datasets to evaluate image intensity variations over time. PERFSCAPE retrieves and accepts data from existing MRI systems. Based on these data, PERFSCAPE performs quality control checks, displays Diffusion Weighted Images and generates parametric perfusion maps such as Relative Cerebral Blood Volume (rCBV), Relative Cerebral Blood Flow (rCBF), Relative Mean Transit Time (rMTT), Time to Peak (TTP) and Impulse Response Time to Peak (TMAX). These images when interpreted by a trained physician may yield information useful in clinical applications.
PERFSCAPE is compliant with the DICOM standard allowing the system to visualize medical images. The system is a multi-platform software running on any Windows, Mac and Linux operating systems.
Product codes (comma separated list FDA assigned to the subject device)
LNH, LLZ
Device Description
PERFSCAPE is a software application designed to analyze dynamically acquired datasets. Using well-established algorithms, parametric perfusion maps can be generated such as Relative Cerebral Blood Volume (rCBV), Relative Cerebral Blood Flow (CBF), Relative Mean Transit Time (MTT), Time to Peak (TTP) and impulse response time to peak (TMAX). The system includes critical features such as:
- Enables rapid creation of a complete array of critical perfusion . parameter maps of rCBV, rCBF, rMTT, TTP, TMAX;
- Automated brain mask generation: .
- View dynamic signal time course on a per-voxel basis; .
- . Interactive Arterial Input Function (AIF) selection:
- Export computed perfusion map to the NEUROSCAPE PACS system. .
PERFSCAPE also allows the user to view the computed perfusion maps using the NEUROSCAPE software. NEUROSCAPE displays the original study series for FLAIR, ADC, B0 and B1000 and PERFSCAPE computed series for TTP, CBV, CBF, MTT and TMAX.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Magnetic Resonance
Anatomical Site
Brain
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Trained physician
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
OLEA Medical has conducted extensive validation testing of the PERFSCAPE system, as a software that is capable of providing reliable postprocessing and display of magnetic resonance perfusion images for instantaneous multi-parametric analysis. All of the different components of the PERFSCAPE software have been stress tested to ensure that the system as a whole provides all the capabilities necessary to operate safely and effectively.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 892.1000 Magnetic resonance diagnostic device.
(a)
Identification. A magnetic resonance diagnostic device is intended for general diagnostic use to present images which reflect the spatial distribution and/or magnetic resonance spectra which reflect frequency and distribution of nuclei exhibiting nuclear magnetic resonance. Other physical parameters derived from the images and/or spectra may also be produced. The device includes hydrogen-1 (proton) imaging, sodium-23 imaging, hydrogen-1 spectroscopy, phosphorus-31 spectroscopy, and chemical shift imaging (preserving simultaneous frequency and spatial information).(b)
Classification. Class II (special controls). A magnetic resonance imaging disposable kit intended for use with a magnetic resonance diagnostic device only is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.
0
JUL 20 2009
510(k) Summary (in accordance with 21 CFR 807.92)
510(k) Number K
I. Applicant Information
Applicant:
OLEA MEDICAL 93 avenue du Sorbier 13600 La Ciotat France
Fayçal Djeridane
Tel: (011) 33 4 42 71 24 20 Fax: (011) 33 4 88 56 53 39
President
Contact Person:
Application Correspondent:
EMERGO GROUP INC. 1705 S. Capital of Texas Hwy., Suite 500 Austin, TX 78746 U.S.A.
e-mail: faycal.djeridane@olea-medical.com
Contact Person:
Neal Kolber Project Manager Tel: (512) 327-9997 Fax: (512) 327-9998 e-mail: neal@emergogroup.com
Date Prepared:
May 4, 2009
II. Device Name and Classification
Proprietary Name: Classification Name: Common/Usual Name: Regulation Number: Product Codes: Classification: Classification Panel:
PERFSCAPE Magnetic Resonance Diagnostic Device Picture Archiving Communications System (PACS) 892.1000 LNH . Class II Radiology Devices
Traditional 510(k) – PERFSCAPE
CONFIDENTIAL
Page 5-1
1
III. Predicate Device
The PERFSCAPE device is substantially equivalent to the following FDA cleared predicate device with regard to indications for use, performance and technological characteristics:
| 510(k) Number: | K080762 |
|---|---|
| Trade Name: | IB Neuro™ 1.0 |
| Manufacturer: | Imaging Biometrics, LLC |
| Classification Name: | Magnetic Resonance Diagnostic Device |
| Common/Usual Name: | Picture Archiving Communications System (PACS) |
| Regulation Number: | 892.1000 |
| Product Codes: | LNH |
| Classification: | Class II |
IV. Device Description
PERFSCAPE is a software application designed to analyze dynamically acquired datasets. Using well-established algorithms, parametric perfusion maps can be generated such as Relative Cerebral Blood Volume (rCBV), Relative Cerebral Blood Flow (CBF), Relative Mean Transit Time (MTT), Time to Peak (TTP) and impulse response time to peak (TMAX). The system includes critical features such as:
- Enables rapid creation of a complete array of critical perfusion . parameter maps of rCBV, rCBF, rMTT, TTP, TMAX;
- Automated brain mask generation: .
- View dynamic signal time course on a per-voxel basis; .
- . Interactive Arterial Input Function (AIF) selection:
- Export computed perfusion map to the NEUROSCAPE PACS system. .
PERFSCAPE also allows the user to view the computed perfusion maps using the NEUROSCAPE software. NEUROSCAPE displays the original study series for FLAIR, ADC, B0 and B1000 and PERFSCAPE computed series for TTP, CBV, CBF, MTT and TMAX.
V. Intended Use
PERFSCAPE allows the post-processing and display of dynamically acquired Magnetic Resonance datasets to evaluate image intensity variations over time. PERFSCAPE retrieves and accepts data from existing MRI systems. Based on these data, PERFSCAPE performs quality control checks, displays Diffusion
Traditional 510(k) - PERFSCAPE
CONFIDENTIAL
Page 5-2
2
Weighted Images and generates parametric perfusion maps such as Relative Cerebral Blood Volume (rCBV), Relative Cerebral Blood Flow (rCBF), Relative Mean Transit Time (rMTT), Time to Peak (TTP) and Impulse Response Time to Peak (TMAX). These images when interpreted by a trained physician may yield information useful in clinical applications.
PERFSCAPE is compliant with the DICOM standard allowing the system to visualize medical images. The system is a multi-platform software running on any Windows, Mac and Linux operating systems.
VI. Summary of the Technical Characteristics
PERFSCAPE is a PACS software designed to access series of MRI perfusion and diffusion images in DICOM format. PERFSCAPE analyzes dynamically acquired MR datasets and generates parametric maps of the brain.
PERFSCAPE allows interactive and multiple selections of arterial input functions and displays map results of the selected slice in real time. The selected AIF can be manually filtered before the beginning of the signal of interest and after the beginning of the recirculation. It also allows generating, manually or automatically, a brain mask to remove non-brain voxels. PERFSCAPE allows creating a NEUROSCAPE study with computed perfusion maps and with imported diffusion map.
VII. Testing
OLEA Medical has conducted extensive validation testing of the PERFSCAPE system, as a software that is capable of providing reliable postprocessing and display of magnetic resonance perfusion images for instantaneous multi-parametric analysis. All of the different components of the PERFSCAPE software have been stress tested to ensure that the system as a whole provides all the capabilities necessary to operate safely and effectively.
VIII. Safety & Effectiveness Conclusions
Based on the comparison of intended use and technological characteristics, the PERFSCAPE system is substantially equivalent to the IB Neuro™ 1.0 device manufactured by Imaging Biometrics, LLC (K080762). The PERFSCAPE device raises no new safety or effectiveness issues.
CONFIDENTIAL
3
Image /page/3/Picture/0 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" arranged around the perimeter. Inside the circle is a stylized symbol that resembles an abstract human figure or a bird in flight, composed of three curved lines.
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
JUL 20 2009
Olea Medical % Mr. Neal Kolber Project Manager Emergo Group, Inc. 1705 S. Capital of Texas Hwy., Suite 500 AUSTIN TX 78746
Re: K091444
Trade/Device Name: PERFSCAPE Regulation Number: 21 CFR 892.2050 Regulation Name: Picture archiving and communications system Regulatory Class: II Product Code: LLZ Dated: May 4, 2009 Received: May 21, 2009
Dear Mr. Kolber:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA). it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical
4
device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH0ffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/cdrl/mdr/ for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Janine M. Morris Acting Director, Division of Reproductive, Abdominal, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
4. Indication for Use Statement
K0914444 510(k) Number (if known):
510(k) Number
Device Name:
PERFSCAPE
Indications for Use:
PERFSCAPE allows the post-processing and display of dynamically acquired Magnetic Resonance datasets to evaluate image intensity variations over time. PERFSCAPE retrieves and accepts data from existing MRI systems. Based on these data, PERFSCAPE performs quality control checks, displays Diffusion Weighted Images and generates parametric perfusion maps such as Relative Cerebral Blood Volume (rCBV), Relative Cerebral Blood Flow (rCBF), Relative Mean Transit Time (rMTT), Time to Peak (TTP) and Impulse Response Time to Peak (TMAX). These images when interpreted by a trained physician may yield information useful in clinical applications.
PERFSCAPE is compliant with the DICOM standard allowing the system to visualize medical images. The system is a multi-platform software running on any Windows, Mac and Linux operating systems.
| Prescription Use _X (Part 21 CFR 801 Subpart D) | AND/OR Over-The-Counter Use (21 CFR 801 Subpart C) |
|---|---|
| ------------------------------------------------- | ---------------------------------------------------- |
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
| (Division Sign-Off) | |
|---|---|
| Division of Reproductive, Abdominal and Radiological Devices |
Page 1 of 1